




**A Continuing Medical Education Activity**  
 The 18th Conference on  
 Retroviruses and Opportunistic Infections (CROI):  
*Online Expert Poster Review and Discussion*

Jointly sponsored by the Postgraduate Institute for Medicine and ViralEd, LLC

**Central Fat Accumulation in Antiretroviral-Naïve Subjects  
 Randomized to Abacavir/Lamivudine or Tenofovir  
 DF/Emtricitabine with Atazanavir/Ritonavir or Efavirenz: AIDS  
 Clinical Trials Group Study A5224s a Substudy of ACTG A5202**

Grace McComsey, D Kitch, P Sax, P Tebas, C Tierney, N Jahed,  
 L Myers, K Melbourne, B Ha, and E Daar


**A5224s:  
 Metabolic Sub-Study of A5202**



# ACTG 524s: Visceral Fat Change by Regimen in A5202


- ATV/r led to greater gains in weight (1.1kg more), trunk fat and a trend to greater gain in VAT than EFV. There were no differences between NRTIs
- Changes in VAT correlated with changes in limb fat ( $r=0.48$ ;  $P<0.001$ )
- Age, sex, race/ethnicity, baseline HIV-1 RNA, CD4 count, and BMI were not associated with week 96 absolute or percent change in VAT

## CT Results: Mean percent change in VAT (ITT, Week 96)



McComsey, G. et al. 18th CROI; Boston, MA; February 27-March 2, 2011. Abst. 77.

# CT Results: Mean (95% CI) Percent Change in SAT (ITT)



McComsey, G. et al. 18th CROI; Boston, MA; February 27-March 2, 2011. Abst. 77.